Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.10 and traded as high as $3.19. Galmed Pharmaceuticals shares last traded at $3.19, with a volume of 33,258 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They set a “sell” rating on the stock.
View Our Latest Analysis on GLMD
Galmed Pharmaceuticals Trading Up 4.1 %
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- 10 Best Airline Stocks to Buy
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- What is Insider Trading? What You Can Learn from Insider Trading
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
